Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Asset Writedowns and Impairment (2016)

Amphastar Pharmaceuticals (AMPH) has 4 years of Asset Writedowns and Impairment data on record, last reported at $114000.0 in Q2 2016.

  • For Q2 2016, Asset Writedowns and Impairment changed N/A year-over-year to $114000.0; the TTM value through Dec 2023 reached $114000.0, changed N/A, while the annual FY2023 figure was $2.7 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached $114000.0 in Q2 2016 per AMPH's latest filing, down from $217000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $217000.0 in Q1 2016 and bottomed at $4000.0 in Q3 2015.
  • Average Asset Writedowns and Impairment over 4 years is $113555.6, with a median of $120000.0 recorded in 2013.
  • The widest YoY moves for Asset Writedowns and Impairment: up 64.1% in 2015, down 69.23% in 2015.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $120000.0 in 2013, then crashed by 35.0% to $78000.0 in 2014, then soared by 64.1% to $128000.0 in 2015, then decreased by 10.94% to $114000.0 in 2016.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $114000.0 in Q2 2016, $217000.0 in Q1 2016, and $128000.0 in Q4 2015.